Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech-Language Pathologists of Ontario(CASLPO), The Association of Public-Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Allied Academies extends its warm welcome to Annual Biotechnology Congress amid August 17-18, 2017 at Toronto, Canada with a subject "New Scientific Developments in Biotechnology of Modern Era".
Degree and Importance
Annual Biotechnology Congress means to unite the Professors, Researchers, researchers, business mammoths, and technocrats to give a global gathering to the spread of unique research comes about, new thoughts and viable improvement and find progresses in the field of biotechnology, administration and instruction in connection to biotechnology and additionally an expansiveness of different subjects. Biotechnology 2017 is a superb open door for the representatives from Universities and Institutes to associate with the world class Scientists.
This biotech meeting makes a
stage for Policy-creators, Scientists, agents and leaders in biotechnology to
display their most recent biotech explore and find out about all the imperative
advancements in biotechnology inquire about. Real subjects talked about are
Biomedicine Engineering, Food Biotechnology, Industrial Biotechnology,
Agriculture Biotechnology, Animal Biotechnology, Environmental Biotechnology,
Marine Biotechnology, Nano biotechnology, Current Scenario of Biotechnology,
Biomass and Bioenergy, Biotechnology
and its Applications, Fighting Cancer with Biotechnology, Biotechnology Market,
Biotech items, Biotech Companies and market investigation, Biotechnology
financial specialists and Grants, Advances in Biotech Manufacturing, Biotech
speculators organize, biotech Market, most recent biotech look into.
Who can go to?
Biotechnology 2017 unites people who have an enthusiasm for various fields of Biotechnology. Target Audience will be work force from both mechanical and scholastic fields which incorporate; Professors, Researchers, researchers, business monsters, CEOs, Directors, Vice Presidents, Co-executives, Bio technologists, Managing Directors, Industry Safety Officers, Environmental and Plant Scientists, Doctorates, Professors, Post Doctorate Fellows, Vendors of Consumer Products/Managers, Pharmaceutical Scientists, Students from the related fields.
Why to Attend???Biotechnology 2017 gives a worldwide stage to trading thoughts and makes us overhauled about the most recent advancements in the field of Biotechnology. Chance to go to the presentations conveyed by Eminent Scientists from everywhere throughout the world.
Target Audience for Biotechnology congress will be personnel from both industrial and academic fields which include;
Head of Departmental
CEO's of biotech companies
Professors, Associate and Assistant professors
Research Scholars and students from the related fields.
Acknowledged modified works will be distributed in specified journals with DOI.
Ecumenical systems administration: In exchanging and trading Conceptions.
· Best Poster Awards.
· Best Start-Up Awards.
· Pre-conference and Conference Workshops.
· Symposiums on Latest Research.
We welcome everyone to participate in Toronto, Canada to advance "Annual Biotechnology Congress"
Allied Academies cordially invites all the participants across the globe from leading universities, clinical research institutions, diagnostic companies and all interested to share their research experiences in the “Annual Biotechnology Congress” during August 17-18, 2017 at Toronto, Canada with the theme of “New Scientific Developments in Biotechnology of Modern Era”.
Track 1: Biochemistry
Biochemistry is the study of the chemical substances and vital processes occurring in live organisms. Biochemists focus heavily on the role, function, and structure of biomolecules. The study of the chemistry behind biological processes and the synthesis of biologically active molecules are examples of biochemistry. The key drivers for molecular biology enzymes, kits and reagents market are the rising R&D expenditure by the pharmaceutical and biotech companies, and increasing public funding for life science research. The World Health Organization estimates that the total aged population may rise from 605 million in 2000 (11% of the global population) to 2 billion by 2050, accounting for 22% of the global population.
Track 2: Molecular Biology
Molecular biology is the study of molecular underpinnings of the processes of replication, transcription, translation, and cell function. The central dogma of molecular biology where genetic material is transcribed into RNA and then translated into protein, despite being an oversimplified picture of molecular biology, still provides a good starting point for understanding the field. This picture, however, is undergoing revision in light of emerging novel roles for RNA.
Track 3: Biomedical Engineering
Medicine is by means of biotechnology techniques so much in diagnosing and treating dissimilar diseases. It also gives opportunity for the population to defend themselves from hazardous diseases. The pasture of biotechnology, genetic engineering, has introduced techniques like gene therapy, recombinant DNA technology and polymerase chain retort which employ genes and DNA molecules to make a diagnosis diseases and put in new and strong genes in the body which put back the injured cells. There are some applications of biotechnology which are live their part in the turf of medicine and giving good results.
This field seeks to close the gap between engineering and medicine. It combines the design and problem solving skills of engineering with medical and biological sciences to advance health care treatment, including diagnosis, monitoring and therapy. Prominent biomedical engineering applications include the development of biocompatible prostheses, various diagnostic and therapeutic medical devices ranging from clinical equipment to micro-implants, common imaging equipment such as MRIs and EEGs, regenerative tissue growth, pharmaceutical drugs and therapeutic biological.
Track 4: Agricultural Biotechnology
Biotechnology is being used to address problems in all areas of agricultural production and processing. This includes plant breeding to raise and stabilize yields; to improve resistance to pests, diseases and abiotic stresses such as drought and cold; and to enhance the nutritional content of foods. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques as Marker Assisted Breeding, which increases the effectiveness of conventional breeding.
Track 5: Animal biotechnology
It improves the food we eat - meat, milk and eggs. Biotechnology can improve an animal’s impact on the environment. Animal biotechnology is the use of science and engineering to modify living organisms. The goal is to make products, to improve animals and to develop microorganisms for specific agricultural uses. It enhances the ability to detect, treat and prevent diseases, include creating transgenic animals (animals with one or more genes introduced by human intervention), using gene knock out technology to make animals with a specific inactivated gene and producing nearly identical animals by somatic cell nuclear transfer (or cloning).
Track 6: Food Processing & Technology
Food processing is a process by which non-palatable and easily perishable raw materials are converted to edible and potable foods and beverages, which have a longer shelf life. Biotechnology helps in improving the edibility, texture, and storage of the food; in preventing the attack of the food, mainly dairy, by the virus like bacteriophage producing antimicrobial effect to destroy the unwanted microorganisms in food that cause toxicity to prevent the formation and degradation of other toxins and anti-nutritional elements present naturally in food.
Track 7: Industrial Biotechnology
Industrial biotechnology is the application of biotechnology for industrial purposes, including industrial fermentation. The practice of using cells such as micro-organisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles and biofuels. Industrial Biotechnology offers a premier forum bridging basic research and R&D with later-stage commercialization for sustainable bio based industrial and environmental applications.
Track 8: Pharmaceutical Biotechnology
Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs. Pharmaceutical Biotechnology is an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs, diagnostic agents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes in healthcare practices and a significant contribution to the development of national economy. Biopharmaceuticals consists of large biological molecules which are proteins. They target the underlying mechanisms and pathways of a disease or ailment; it is a relatively young industry. They can deal with targets in humans that are not accessible with traditional medicines.
Track 9: Environmental biotechnology
Biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one tries to harness biological process for commercial uses and exploitation. The development, use and regulation of biological systems for remediation of contaminated environments and for environment-friendly processes (green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food, and nutrients in a synergistically integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".
Track 10: Genetic & Tissue Engineering
One kind of biotechnology is gene technology, sometimes called 'genetic engineering' or 'genetic modification', where the genetic material of living things is deliberately altered to enhance or remove a particular trait and allow the organism to perform new functions. Genes within a species can be modified, or genes can be moved from one species to another.
Tissue engineering is emerging as a significant potential alternative or complementary solution, whereby tissue and organ failure is addressed by implanting natural, synthetic, or semisynthetic tissue and organ mimics that are fully functional from the start or that grow into the required functionality. Initial efforts have focused on skin equivalents for treating burns, but an increasing number of tissue types are now being engineered, as well as biomaterials and scaffolds used as delivery systems. A variety of approaches are used to coax differentiated or undifferentiated cells, such as stem cells, into the desired cell type. Notable results include tissue-engineered bone, blood vessels, liver, muscle, and even nerve conduits. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.
Track 11: Nano Biotechnology
Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found in Nano biology involve applying Nano tools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology.
Track 12: Bioinformatics
Bioinformatics is the application of computer technology to the management of biological information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied to gene-based drug discovery and development. The science of Bioinformatics, which is the melding of molecular biology with computer science, is essential to the use of genomic information in understanding human diseases and in the identification of new molecular targets for drug discovery.
Every new business needs some startup capital, for research, product development and production, permits and licensing and other overhead costs, in addition to what is needed to pay your staff, if you have any. Biotechnology products arise from successful biotech companies. These companies are built by talented individuals in possession of a scientific breakthrough that is translated into a product or service idea, which is ultimately brought into commercialization. At the heart of this effort is the biotech entrepreneur, who forms the company with a vision they believe will benefit the lives and health of countless individuals. Entrepreneurs start biotechnology companies for various reasons, but creating revolutionary products and tools that impact the lives of potentially millions of people are one of the fundamental reasons why all entrepreneurs start biotechnology companies.
Biotechnology Market Analysis:
industry, part of the life sciences sector has emerged as an attractive segment
and is expected to grow by 37 percent at a Compound Annual Growth Rate (CAGR)
of 8.2 percent over the four-year period 2017-21. This growth, although single
digit, is significantly higher than the more traditional segments in the life
sciences sector, such as pharmaceuticals (expected to grow at a CAGR of
approximately 4 percent during 2015-19)..
The Americas and Europe currently account for the largest share in the global biotechnology market. Although, due to favorable government policies, a relatively low cost of conducting clinical trials and manufacturing products, and an improving healthcare ecosystem, higher growth is expected in the Asia Pacific (APAC) region.
The global biotechnology market size was valued at USD 270.5 billion in 2013 and is expected to grow at a CAGR of 12.3% owing to the increasing demand for diagnostics and therapeutics solutions such as recombinant technology, red biotechnology, and DNA sequencing. The increasing prevalence of diseases such as cancer, hepatitis B, and other orphan disorders is expected to serve as a high-impact rendering driver for this industry over the forecast period. Rising government initiatives owing to high significance towards growth of the economy are expected to boost the biotechnology market growth over the forecast period. Increasing demand for agricultural and food products such as wheat, rice, sugarcane, and beans owing to growing population base in countries such as the U.S., China, and India is another major factor positively impacting the growth of the industry. Factors such as limited availability of agricultural land, shortage of water, the low yield of crops, and pest attacks are encouraging researchers to develop innovative agricultural technologies via extensive R&D activities. Application of biotechnological processes such as Genetic Modification (GM) and genetic engineering on agricultural products is a major driver for the growth of this industry. Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market.
Biotechnology firms’ focus on novel pharmaceutical compounds distinguishes them from the larger, more well-known pharmaceutical companies. During the 10-year period ended December 31, 2014, the largest biotechnology ETF in the world, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB), provided investors an annual total return of 15.1%. The S&P 500 Index returned 7.7% per year over the same period. Such eye-popping returns naturally attract the attention of investors.Biotech drug sales were an estimated $289 billion in 2014 and are projected to grow to $445 billion by 2019 (Figure 2).11 In addition, biotech’s share of worldwide prescription drug and over-the-counter pharma sales is projected to increase from 23 percent in 2014 to 26 percent in 2019. European nations are rushing to develop home-grown biotechnology industries. In the process, they must deal with difficulties obtaining venture capital, conservative attitudes toward commercial risk, and frequently suspicious public opinion.
Outlook on Biotechnology Applications.
Global biotechnology market, based on application, is divided into biopharmaceutical, bio services, bio agriculture, and bio industrial. In 2014, biopharmaceuticals products such as advanced drugs, orphan drugs, monoclonal antibodies, and recombinant proteins dominated the overall industry with around USD 184.21 billion revenue. The sales of the 30 best selling antibodies and proteins in 2014 are listed up, each of them posting more than US$ 1 bln sales in 2014. The report compiles 2014 sales of the major therapeutic proteins per class: erythropoietin, insulin and insulin analogs, coagulation factors, interferon alpha, interferon beta, granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH), enzyme replacement therapy and follicle stimulating hormone (FSH). The report compiles 2014 sales of therapeutic antibodies per class: cancer antibodies, anti-TNF antibodies, other anti-inflammatory antibodies, ophthalmic and antiviral antibodies as well as other therapeutic antibodies. According to an investigation by Ernst and Young relating to the German biotech industry, 92% of companies are currently (2004) working in the field of red biotechnology, 13% in green, and 13% in gray or white biotechnology (environmental and industrial production contexts).
Biologics (biotech drugs, biological drugs, and biopharmaceuticals) include a wide range of products such as vaccines, therapeutic proteins, blood and blood components, tissues, etc. The global biologics market totaled $200.6 billion in 2013 and is expected to grow to nearly $234 billion in 2014. The total market is expected to grow to $386.7 billion by the end of 2019 at compound annual growth rate (CAGR) of 10.6%. Biologic agents will continue to outpace overall pharma spending growth and are expected to represent 19-20% of the total market value by 2017. • Biologics growth is driven by Monoclonal Antibodies (MABs) and human insulin, with four out of the top five biologics in 2012 being MABs.
Biotechnology in Canada:
As per National Household Survey information, in 2015 natural technologists and specialists worked in various ventures. Around 36% worked in expert, logical and specialised administrations, principally in logical innovative work administrations (15%), 23% out in the open organisation and 17% in the assembling area, particularly in substance producing (10%) and in sustenance fabricating (5%). A huge number additionally worked and in instructive administrations labs and research offices (7%) and in horticulture (6%).
Since 2010, the high estimation of the Canadian dollar has come about not just in a slower increment in the genuine esteem (after expansion) of fares, yet it has likewise prompted to a sharp increment in the genuine estimation of imports. Thus, the development in the local request has been focused for the most part on imports, their genuine esteem having developed by more than 65% somewhere around 20012 and 2015, while the genuine estimation of residential generation has expanded by just 6%.
Throughout the following quite a long while, the estimation of the Canadian dollar ought to stay high. It is hence expected that the development in the local request will profit neighbourhood industry to a more noteworthy degree. Thus, generation and work in this industry are relied upon to increment somewhat over the coming years.
University of Toronto, Canada
University of Calgary, Canada
Carleton University, Canada
University of Manitoba, Canada
McMaster University, Canada
Brock University, Canada
Lakehead University, Canada
University of Cambridge, United States
Stanford University, California, United States
University of Oxford, United States
Massachusetts Institute of Technology, United States
University of Washington, Seattle, United States
DNA Genotek Inc.
ProMIS Neurosciences, Inc.
Prairie Plant Systems
Akshaya Bio Inc.
Oncolytics Biotech Inc
Phyton Biotech LLC
Gilead Sciences Canada, Inc.
Qu Biologics Inc
Algaecan Biotech Ltd.
Octane Biotech Inc
Biogen Canada Inc
Kam Biotechnology Ltd
Hess Associates Executive Search